| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | AF-1; IFGR2; IFNGT1 |
| WB Predicted band size | 38 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human IFNGR2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IFNGR2抗体的3篇文献示例(内容为模拟生成，非真实文献)：
1. **"Monoclonal antibody characterization of IFNGR2 in primary immunodeficiency disorders"**
- **作者**: Smith A, et al.
- **摘要**: 研究通过开发特异性IFNGR2单克隆抗体，揭示了IFNGR2基因突变导致的受体表达缺失与严重免疫缺陷疾病(如分枝杆菌感染易感性)的关联。
2. **"Structural insights into IFNGR2 signaling using conformation-specific antibodies"**
- **作者**: Lee JH, et al.
- **摘要**: 利用构象特异性抗体解析IFNGR2与IFN-γ结合后的二聚化机制，阐明了受体激活下游JAK-STAT信号通路的分子结构基础。
3. **"IFNGR2 antibody-based detection in tumor microenvironment profiling"**
- **作者**: Zhang Y, et al.
- **摘要**: 开发高灵敏度IFNGR2多克隆抗体，用于肿瘤组织中受体表达水平的定量分析，发现其与免疫治疗响应率的相关性。
注：以上文献为示例，实际引用需根据PubMed或学术数据库检索真实研究。
The interferon gamma receptor 2 (IFNGR2) is a critical component of the IFN-γ receptor complex, mediating immune responses by facilitating signal transduction upon IFN-γ binding. As a type II cytokine receptor, IFNGR2 pairs with IFNGR1 to form a functional heterodimeric receptor. Upon ligand engagement, it activates the JAK-STAT signaling pathway, triggering the expression of genes involved in antimicrobial defense, immune regulation, and tumor surveillance.
IFNGR2 antibodies are essential tools for studying receptor expression, localization, and signaling mechanisms in immune cells, such as macrophages and T cells. They are widely used in research applications, including Western blotting, flow cytometry, and immunohistochemistry, to investigate IFN-γ-mediated immune dysregulation. Clinically, mutations in IFNGR2 are linked to rare primary immunodeficiency disorders, particularly Mendelian susceptibility to mycobacterial diseases (MSMD), where impaired IFN-γ signaling predisposes individuals to severe infections. Antibodies targeting IFNGR2 aid in diagnosing these genetic defects and elucidating their molecular basis.
Additionally, IFNGR2 antibodies have therapeutic potential, serving as blockers or agonists to modulate IFN-γ pathways in autoimmune diseases or cancer immunotherapy. Their specificity and utility in both basic and translational research underscore their importance in advancing immunology and precision medicine.
×
